# HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects

> **NCT06520540** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.** · enrollment: 72 (estimated)

## Conditions studied

- Glucagon-Like Peptide-1 Receptor Agonists

## Interventions

- **DRUG:** HDM1002 100 mg QD 12weeks
- **DRUG:** HDM1002 200 mg QD 12weeks
- **DRUG:** HDM1002 400 mg QD 12weeks，Q 2W for titration
- **DRUG:** HDM1002 400 mg QD 12weeks，Q 3W for titration
- **DEVICE:** Placebo

## Key facts

- **NCT ID:** NCT06520540
- **Lead sponsor:** Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-28
- **Primary completion:** 2024-11-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2024-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06520540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06520540, "HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06520540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*